PharmiWeb Recruiter Blog

Posts by

Editor

ICON

ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others

Dublin, Ireland – 13 December 2022 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been recognised with a number of coveted business and industry awards over the second half of 2022 for delivering clinical research services, alongside specialist collaborations on data, analytics and digital healthcare.

Read more
GSK

GSK announces new global headquarters in central London

  • Location offers closer proximity to UK capital’s fast-growing global Life Sciences hub, Knowledge Quarter and world-class academic institutions
  • Building and location will help GSK achieve ambitious sustainability targets
  • Company to open new headquarters in 2024

GSK plc (LSE/NYSE: GSK) today announced that its new global headquarters will be in central London. The company will move to the new headquarters in 2024 from its current location in Brentford, West London.

Read more
Merck

Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO). On Nov. 21, 2022, Merck announced that it had entered into a definitive agreement to acquire Imago.

Read more
AbbVie

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

  • Collaboration leverages HotSpot's Smart Allostery™ drug discovery platform for the development of the first and only small molecule IRF5 (interferon regulatory factor 5) inhibitor for the potential treatment of autoimmune diseases
  • HotSpot to receive an upfront cash payment of $40 million with potential for further milestones and royalties

NORTH CHICAGO, Ill. and BOSTON, Dec. 6, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.

Read more